278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients von Krastev, B., Rai, R., Bulat, I., Maglakelidze, M., Murias, C., Arkenau, H-T., Baird, R.D., Wardley, A.M., Roylance, R., Crijanovschi, A., Gogiladze, M., Tao, W., Beelen, A.P., Sorrentino, J.A.

Volltext

334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection von Bulat, I., Maglakelidze, M., Krastev, B., Arkenau, H-T., Murias, C., Baird, R.D., Roylance, R., Wardley, A.M., Crijanovschi, A., Gogiladze, M., Lu, Y., McCullough, A., Jain, S., Wolfgang, C.D., Malik, R., Beelen, A.P.

Volltext

The restoration of the function of the hypophyseal-gonadal system following its prolonged suppression by luliberin agonists von Goncharova, N D, Mkhitarova, L A, Gogiladze, E M

Volltext

Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with... von Bulat, Iurie, Maglakelidze, Marina, Murias, Carmen, Krastev, Boris, Baird, Richard D, Wardley, Andrew M, Roylance, Rebecca, Crijanovschi, Adrian, Gogiladze, Maia, Pritchett, Yili, McCullough, Amy, Li, Chao, Sorrentino, Jessica A, Malik, Rajesh, Beelen, Andrew P

Volltext